GO Therapeutics is exploiting unique aspects of cancer cell biology to develop a new class of cancer therapies for previously intractable solid tumors. LEARN MORE.
We target O-linked glycoproteins specific to cancer cells to develop proprietary, high-affinity antibodies to novel cancer-specific targets.
Our antibodies are the basis for a broad array of potent cancer-killing modalities including T-cell bispecifics, CAR-T, and ADCs. VIEW PIPELINE.
Each antibody is designed to kill cancer while sparing healthy tissue.
Exploiting advances in glycoprotein biology to develop cancer-specific targets for treating solid tumors.
Developing a new class of high-affinity cancer-specific antibodies.
Arming our antibodies with cutting-edge potent cancer-killing modalities to deliver exceptional efficacy and safety.
Integrating our proprietary cancer-specific therapeutics into combination therapies to herald a new era of cancer treatment.